Prelude Therapeutics

46 articles about Prelude Therapeutics

• Prelude Therapeutics Announces Pricing of Public Offering

  5/18/2023

  Prelude Therapeutics Incorporated today announced the pricing of its underwritten public offering of 3,048,522 shares of its voting common stock and 1,448,222 shares of its non-voting common stock, each at a price to the public of $5.75 per share, and, in lieu of common stock to investors who so choose.

• Prelude Therapeutics Announces Launch of Proposed Public Offering - May 17, 2023

  5/17/2023

  Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, announced that it has commenced an underwritten public offering of $100.0 million of shares of common stock and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase shares of common stock.

• Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

  5/8/2023

  Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2023, and provided an update on recent clinical and development pipeline progress.

• Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

  4/27/2023

  Prelude Therapeutics Incorporated today announced that company executives will participate in three upcoming healthcare investment conferences.

• Prelude Therapeutics to Present at American Association for Cancer Research 2023 ConferenceEight Abstracts Demonstrate Progress of Prelude’s Differentiated Pipeline

  4/11/2023

  Prelude Therapeutics Incorporated today announced details relating to eight abstracts being presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.

• Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

  3/15/2023

  Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2022, and provided a corporate update.   

• Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

  3/15/2023

  Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced a clinical trial collaboration with BeiGene, for future evaluation of its investigational CDK9 inhibitor, PRT2527, in combination with BeiGene’s BTK inhibitor, zanubrutinib, in hematologic malignancies.

• Prelude Therapeutics To Participate in Barclays Global Healthcare Conference

  3/1/2023

  Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Barclays Global Healthcare Conference in Miami, March 14 to 16, 2023.

• Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

  2/9/2023

  Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in three healthcare investment conferences in February.

• Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

  11/14/2022

  Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2022 and provided an update on recent clinical and development pipeline progress.

• Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader

  10/18/2022

  Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, announced that the U.S. Food and Drug Administration, cleared the company to proceed with a Phase 1 study under its Investigational New Drug Application for PRT3789, a first-in-class potent and selective SMARCA2 protein degrader.

• Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

  8/9/2022

  Prelude Therapeutics Incorporated today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent clinical and development pipeline progress.

• Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

  5/10/2022

  Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022, and provided an update on recent clinical and development pipeline progress.

• PreludeDx™ Closes $20 Million in Funding to Advance Growth Initiatives and Development of Its Precision Medicine Portfolio

  3/22/2022

  Prelude Corporation, a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced that it has closed a $20 million funding round led by Evidity Health Capital and joined by existing and new investors.

• Prelude Therapeutics Reports Full Year 2021 Financial Results

  3/16/2022

  Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2021.

• Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference

  3/11/2022

  Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will participate in a fireside chat at the Barclays 2022 Global Healthcare Conference in Miami, FL on Thursday, March 17, 2022 at 9:00 a.m. ET.

• 

  BioSpace Movers & Shakers, March 11

  3/11/2022

  Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers

• Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting

  3/9/2022

  Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today provided a clinical update on its diverse and growing pipeline and announced that new preclinical data have been accepted for presentation at the upcoming 2022 American Association for Cancer Research (AACR) Annual Meeting being held April 8-13 in New Orleans, Louisiana.

• Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer

  3/9/2022

  Prelude Therapeutics Incorporated a clinical-stage precision oncology company, announced that Jane Huang, M.D., has been appointed to the newly created position of President and Chief Medical Officer, effective on April 4, 2022.

• Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

  2/11/2022

  Prelude Therapeutics Inc., a clinical-stage precision oncology company, announced that Kris Vaddi, PhD, Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18 at 1:40 p.m. ET.